Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: Application to amitriptyline N-demethylation

British Journal of Clinical Pharmacology

Volumn 41, Issue 6, 1996, Pages 593-604

  Schmider, Jürgen ^a   Greenblatt, David J ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akaike's Information Criterion; amitriptyline; cytochrome P450; enzyme kinetics; Michaelis Menten equation; nonlinear regression

Indexed keywords

AMITRIPTYLINE; CYTOCHROME P450; KETOCONAZOLE; MEPHENYTOIN; NORTRIPTYLINE; SULFAPHENAZOLE;

ALLOSTERISM; ARTICLE; DEMETHYLATION; DOSE RESPONSE; DRUG TRANSFORMATION; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS CONSTANT; PRIORITY JOURNAL;

EID: 0029934305     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.35717.x     Document Type: Article

References (35)

1. Warner M, Gustafsson JA. Extrahepatic microsomal forms: brain cytochrome P450. In Cytochrome P450. eds Schenkman JB, Greim H, Berlin: Springer Verlag, 1993: 387-97.
2. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90: 1871-1878.
3. Kolars JC, Awni WC, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-1490.
4. Herbert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporine with concomitant rifampicin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992; 52: 453-457.
5. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms, and effect of metabolic inhibitors. J Pharmacol Exp Ther 1995; 275: 592-597.
6. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Duan SX, Karsov D, Shader RI. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450 directed antibodies. Pharmacology 1996; 52: 125-134.
7. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 1996; (in press).
8. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Cytochromes in psychopharmacology. J Clin Psychopharmacol 1994; 14: 1-4.
9. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
10. Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1987; 1: 365-374.
11. Boxenbaum HG, Riegelman S, Elashoff RM. Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 1974; 2: 123-148.
12. Akaike H. An information criterion (AIC). Math Sci 1976; 14: 5-9.
13. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm 1978; 6: 165-175.
14. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993; 47: 268-276.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283.
16. Halvorson M, Greenway D, Eberhart D, Fitzgerald K, Parkinson A. Reconstitution of testosterone oxidation by purified rat cytochrome P450p (IIIA1). Arch Biochem Biophys 1990; 277: 166-180.
17. Norby J, Rubenstein S, Tuerke T, Farmer S, Forood R, Bennington J. SigmaPlot, v. 4.13. Jandel Corporation 1991.
18. Mannervik B. Design and analysis of kinetic experiments for discrimination between rival models. In Kinetic data analysis. eds Endrenyi L, New York: Plenum Press, 1981: 235-270.
19. Cornish-Bowden A. Principles of enzyme kinetics. London-Boston: Butterworths, 1976: 66-67.
20. Segel IH. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. New York: Wiley & Sons, Inc., 1975: 346-462.
21. Bardsley WG, Leff P, Kavanagh J, Waight RD. Deviations from Michaelis-Menten kinetics. The possibility of complicated curves for simple kinetic schemes and the computer fitting of experimental data for acetylcholinesterase, acid phosphatase, adenosine deaminase, arylsulphatase, benzylamine oxidase, chymotrypsin, fumarase, galactose dehydrogenase, beta-galactosidase, lactate dehydrogenase, peroxidase and xanthine oxidase. Biochem J 1980; 187: 739-765.
22. Jeng YJ, Martin A. Residuals in multiple regression analysis. J Pharm Sci 1985; 74: 1053-57.
23. Pratt WB, Taylor P. Principles of drug action. 3rd edition. Eds Pratt WB, Taylor P. New York, Edinburgh, London, Melbourne: Churchill Livingstone Inc., 1990: 54.
24. Andersson T, Miners JO, Veronese ME, Birkett DJ. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38: 131-137.
25. Schwab GE, Raucy JL, Johnson EF. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 1988; 33: 493-499.
26. Shou M, Grogan J, Mancewicz JA, et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450-6455.
27. Newton DJ. Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
28. Baumann P, Jonzier-Perey M, Koeb L, Küpfer A, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986: 1: 102-112.
29. Breyer-Pfaff U, Pfandl B, Nill K. et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350-358.
30. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33: 1743-1752.
31. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Archiv Biochem Biophys 1993; 306: 240-245.
32. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
33. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989; 36: 89-96.
34. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992; 44: 275-283.
35. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23.